ArticleOncology letters2026
Primary intracranial extraskeletal myxoid chondrosarcoma in a teenager with unusual frontal location and surgical complications: A case report and literature review.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary intracranial extraskeletal myxoid chondrosarcoma (EMC) is rare and diagnostically challenging, with only sporadic pediatric and adolescent cases reported. The current study describes the case of a 17-year-old male presenting with an acute headache, nausea and emesis. Neuroimaging revealed a 7.2×5.2-cm hemorrhagic mass in the right frontal lobe with involvement of the anterior skull base. A gross total resection was achieved. Histopathology confirmed EMC with high-grade features, including loss of integrase interactor 1 (INI1) expression and a Ki-67 labeling index of 80%. The postoperative course was complicated by bacterial meningitis, which resolved with antibiotics. Adjuvant radiotherapy was delivered to the tumor bed and involved the dura at 66 Gy in 33 fractions without major toxicity. At the 3-month follow-up, there was no evidence of recurrence. This presentation, namely frontal-lobe localization in an adolescent and an aggressive immunophenotype with INI1 loss, is uncommon for intracranial EMC, which is more frequently described in middle-aged patients and posterior fossa sites. Molecular subtyping, which can inform targeted therapy selection, was not performed due to financial constraints. The diagnosis relied on multimodal integration of imaging, histology and immunohistochemistry; key mimics were disfavored by negative staining for glial fibrillary acidic protein, epithelial membrane antigen, desmin and S-100 protein. Given the pathological risk profile and the anticipated limited benefit of chemotherapy, systemic therapy was not pursued. The patient's long-term prognosis remains uncertain, and imaging surveillance is planned at 3- to 6-month intervals for 2 years and annually thereafter. This case highlights the importance of considering EMC in the differential diagnosis of young patients presenting with aggressive, hemorrhagic intracranial masses, particularly those with INI1 loss, and underscores the need for multimodal diagnostic approaches in such rare entities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.